Recalls / Class I
Class ID-0388-2026
Class I— FDA's most serious classification, issued when there is a reasonable probability that use of or exposure to the drug will cause serious adverse health consequences or death.
Product
SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China
- Affected lot / code info
- All lots within expiry
Why it was recalled
Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.
Recalling firm
- Firm
- ANTHONY TRINH, 123Herbals LLC
- Notification channel
- Press Release
- Type
- Voluntary: Firm initiated
- Address
- 7214 Berne St, N/A, Rosemead, California 91770-3844
Distribution
- Quantity
- N/A
- Distribution pattern
- USA nationwide
Timeline
- Recall initiated
- 2025-10-20
- FDA classified
- 2026-03-13
- Posted by FDA
- 2026-03-11
- Status
- Ongoing
Source: openFDA Drug Enforcement endpoint. Recall record D-0388-2026. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.